Sheaff Brock Investment Advisors LLC boosted its holdings in CVS Health Corp (NYSE:CVS) by 11.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,489 shares of the pharmacy operator’s stock after purchasing an additional 1,655 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in CVS Health were worth $898,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Robecosam AG boosted its holdings in CVS Health by 17.8% in the second quarter. Robecosam AG now owns 220,965 shares of the pharmacy operator’s stock valued at $12,096,000 after purchasing an additional 33,409 shares in the last quarter. Cibc Bank USA boosted its holdings in CVS Health by 5.3% in the second quarter. Cibc Bank USA now owns 10,215 shares of the pharmacy operator’s stock valued at $557,000 after purchasing an additional 518 shares in the last quarter. Stevens Capital Management LP boosted its holdings in CVS Health by 109.1% in the second quarter. Stevens Capital Management LP now owns 444,179 shares of the pharmacy operator’s stock valued at $24,203,000 after purchasing an additional 231,718 shares in the last quarter. Benin Management CORP boosted its holdings in CVS Health by 50.2% in the second quarter. Benin Management CORP now owns 15,389 shares of the pharmacy operator’s stock valued at $839,000 after purchasing an additional 5,145 shares in the last quarter. Finally, CWM LLC boosted its holdings in CVS Health by 7.2% in the second quarter. CWM LLC now owns 5,585 shares of the pharmacy operator’s stock valued at $304,000 after purchasing an additional 374 shares in the last quarter. 77.18% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE CVS traded down $0.72 during mid-day trading on Wednesday, hitting $59.13. 311,359 shares of the company were exchanged, compared to its average volume of 11,224,507. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.64 and a current ratio of 0.95. The business’s 50 day moving average is $56.12. CVS Health Corp has a 1-year low of $51.72 and a 1-year high of $82.15. The company has a market capitalization of $77.11 billion, a price-to-earnings ratio of 8.34, a price-to-earnings-growth ratio of 1.30 and a beta of 0.90.
CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.70 by $0.19. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The firm had revenue of $63.43 billion during the quarter, compared to the consensus estimate of $62.66 billion. During the same period last year, the company earned $1.69 earnings per share. The company’s revenue for the quarter was up 35.2% on a year-over-year basis. On average, equities analysts anticipate that CVS Health Corp will post 6.96 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, August 2nd. Investors of record on Thursday, July 25th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 3.38%. The ex-dividend date was Wednesday, July 24th. CVS Health’s dividend payout ratio is presently 28.25%.
A number of equities analysts recently issued reports on the company. Standpoint Research raised CVS Health from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. UBS Group decreased their price objective on CVS Health from $74.00 to $67.00 and set a “sell” rating for the company in a report on Thursday, May 2nd. Evercore ISI set a $63.00 price objective on CVS Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Mizuho set a $71.00 price objective on CVS Health and gave the company a “buy” rating in a report on Wednesday, June 5th. Finally, Credit Suisse Group downgraded CVS Health from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $73.00 to $61.00 in a report on Monday, April 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $75.14.
CVS Health Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.